On June 11, 2025, the U.S. Court of Appeals for the Federal Circuit decided Agilent Technologies, Inc. v. Synthego Corp. (No. 23-2186), addressing enablement of prior art references for disputed CRISPR-Cas9 gene-editing...more
On May 12, 2025, the U.S. Court of Appeals for the Federal Circuit issued a long-awaited decision in Regents of the University of California v. Broad Institute (Nos. 22-1594, 22-1653) addressing priority for disputed...more
5/28/2025
/ Appeals ,
Biotechnology ,
CRISPR ,
Intellectual Property Litigation ,
Inventions ,
Life Sciences ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Patents ,
Technology
After decades of drafting and negotiating, the Unified Patent Court ("UPC") is finally set to go ahead. The year 2022 has been dynamic for this new European court: The regulations on the unitary patent entered into force...more
How has President Trump's "America First" philosophy affected US patent policy? White & Case partners discussed what an evolving US patent policy will mean for other nations, and to propose effective responses....more
7/26/2019
/ Broadest Reasonable Interpretation Standard ,
Claim Amendments ,
Claim Construction ,
Diagnostic Method ,
International Summits ,
Japan ,
Life Sciences ,
Patent Trial and Appeal Board ,
Patent Trolls ,
Patent-Eligible Subject Matter ,
Patents ,
Post-Grant Review ,
Presidential Appointments ,
Treatment Method Patents ,
Trump Administration ,
United States ,
USPTO